Compare BridgeBio Pharma Inc (BBIO) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Las Vegas Sands Corp. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Las Vegas Sands Corp. trades at $45.83 (market cap $29.44B). The key difference: Las Vegas Sands Corp. is the larger of the two by market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | LVS | |
|---|---|---|
Market Cap | $16.61B | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $69.49 |
52-Week Low | $47.29 | $44.78 |
Enterprise Value | $18.16B | $41.33B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
LVS trades at $45.77, down 0.74% on the day, with a bearish technical signal and recent Q2 2026 earnings miss. The company shows strong fundamentals with revenue growth to $13.02B in 2025, a net income margin of 12.59%, and robust cash flow from operations of $3.02B. Analyst consensus remains bullish with a $60.75 price target and 59% buy ratings, supported by positive corporate news on ESG achievements and community initiatives.
The outlook for LVS is mixed; strong profitability and analyst optimism contrast with technical bearishness and high debt levels. Upside potential exists if earnings rebound, but risks include competitive pressures and macroeconomic sensitivity. The stock's current valuation at a P/E of 17.74 offers a reasonable entry if operational execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
